Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | CASR | P41180 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227140 | 1.00 | APAF1 (0.63) | APAF1CYP3A4CHRM2HTR1AADRA2A | |
| SCHEMBL5228652 | 1.00 | APAF1 (0.63) | APAF1CYP3A4CHRM2HTR1AADRA2A | |
| SCHEMBL7792066 | 0.84 | APAF1 (0.61) | APAF1CYP3A4CHRM2HTR1AADRA2A | |
| SCHEMBL30285806 | 0.83 | APAF1 (0.65) | APAF1CYP3A4CHRM2HTR1AADRA2A | |
| SCHEMBL8090952 | 0.83 | APAF1 (0.65) | APAF1CYP3A4CHRM2HTR1AADRA2A | |
| SCHEMBL8090949 | 0.83 | APAF1 (0.65) | APAF1CYP3A4CHRM2HTR1AADRA2A | |
| SCHEMBL17509718 | 0.83 | ANPEP (0.62) | APAF1CYP3A4CHRM2HTR1AADRA2A | |
| SCHEMBL24406703 | 0.81 | CYP3A4 (0.76) | APAF1CYP3A4CHRM2HTR1AADRA2A | |
| SCHEMBL3881699 | 0.81 | CYP3A4 (0.76) | APAF1CYP3A4CHRM2HTR1AADRA2A | |
| SCHEMBL3881700 | 0.81 | CYP3A4 (0.76) | APAF1CYP3A4CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| CN-100558701-C | N-(2-phenylethyl) sulfone amide derivative as integrin alpha 4 antagonists | ALMIRALL PRODESFARMA SA (ES) | 2009-11-11 | — | — | CN | disclosed |
| CN-1816523-A | N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists | ALMIRALL PRODESFARMA SA (ES) | 2006-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | APAF1 2600/4885CYP3A4 100/4885CHRM2 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.